M. Pishvain

Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events

N. Rizvi, H. Kluger, M. Callahan, 2016 .